Diabetes Clinical Trials in San Antonio, TX

52 recruiting studies within 50 miles

Phase

Trial	Phase	Sponsor	Dist.
Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes	N/A	Endogenex, Inc.	<1 mi
Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)	N/A	The University of Texas Health Science Center at San Antonio	<1 mi
SGLTi, Hepatic Glucose Production and Ketogenesis	Phase 1	The University of Texas Health Science Center at San Antonio	<1 mi
Bionic Pancreas in CFRD	Phase 3	Jaeb Center for Health Research	<1 mi
Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)	Phase 1	Gilead Sciences	<1 mi
Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes	Phase 3	The University of Texas Health Science Center at San Antonio	<1 mi
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease	Phase 3	Prokidney	<1 mi
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes	Phase 3	Eli Lilly and Company	<1 mi
Pioglitazone on Heart Failure in Type-2 Diabetes Mellitus Participants	Phase 4	The University of Texas Health Science Center at San Antonio	<1 mi
Mirragen Diabetic Foot Ulcer Study	—	The University of Texas Health Science Center at San Antonio	<1 mi
ROME GS System Study	N/A	Senseonics, Inc.	<1 mi
Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes	Phase 3	vTv Therapeutics	<1 mi
Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease	Phase 2	Regeneron Pharmaceuticals	<1 mi
Dapagliflozin Plus Pioglitazone in T1DM	Phase 4	The University of Texas Health Science Center at San Antonio	<1 mi
Study of WAL0921 in Patients With Glomerular Kidney Diseases	Phase 2	Walden Biosciences	<1 mi
Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity	Phase 2	Kailera	<1 mi
Fenofibrate for Prevention of DR Worsening	Phase 3	Jaeb Center for Health Research	<1 mi
HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes	Phase 2	Housey Healthcare ULC	<1 mi
Transformative Research in Diabetic Nephropathy	—	University of Pennsylvania	<1 mi
SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes	Phase 2	SAb Biotherapeutics, Inc.	<1 mi
SGLT2i, Ketoacidosis, Volume Contraction, and Insulinopenia	Phase 1	The University of Texas Health Science Center at San Antonio	<1 mi
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease	Phase 2	Novo Nordisk A/S	<1 mi
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease	Phase 3	Boehringer Ingelheim	<1 mi
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma	Phase 2	Children's Oncology Group	<1 mi
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes	Phase 3	Kailera	<1 mi
Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy	Phase 2	Biomea Fusion Inc.	<1 mi
A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes	Phase 2	Zucara Therapeutics Inc.	<1 mi
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes	Phase 3	Eli Lilly and Company	<1 mi
CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)	Phase 1/2	COUR Pharmaceutical Development Company, Inc.	<1 mi
A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome	Phase 3	NewAmsterdam Pharma	<1 mi
Prevention of Progression of Prediabetes, Obesity and CV Risk	Phase 1	The University of Texas Health Science Center at San Antonio	<1 mi
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort	Phase 1	AstraZeneca	<1 mi
Matrion Decellularized Placental Membrane Versus Conventional Wound Management in Subjects With Diabetic Foot Ulcers	N/A	LifeNet Health	<1 mi
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin	Phase 3	Eli Lilly and Company	<1 mi
Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM)	—	Jaeb Center for Health Research	<1 mi
SGLT2i, Pioglitazone, and Ketone Production in T2D	Phase 1	The University of Texas Health Science Center at San Antonio	<1 mi
SGLT2i, Hepatic Glucose Production, and SNS	Early 1	The University of Texas Health Science Center at San Antonio	<1 mi
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes	Phase 3	Novo Nordisk A/S	<1 mi
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight	Phase 3	Novo Nordisk A/S	<1 mi
Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes	Phase 4	Marzieh Salehi	<1 mi
A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus	Phase 2	Corxel Pharmaceuticals	<1 mi
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes	Phase 1	Eli Lilly and Company	<1 mi
SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan	Early 1	The University of Texas Health Science Center at San Antonio	<1 mi
Acute and Chronic Effects of Oral Ketones in Subjects With HFrEF and Diabetes	Early 1	The University of Texas Health Science Center at San Antonio	<1 mi
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis	Phase 2/3	CSL Behring	<1 mi
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer	Phase 1/2	Aulos Bioscience, Inc.	<1 mi
Quantifying Hepatic Mitochondrial Fluxes in Humans	Phase 4	The University of Texas Health Science Center at San Antonio	<1 mi
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide	Phase 2	Eli Lilly and Company	12 mi
A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin	Phase 2	Eli Lilly and Company	12 mi
A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes	Phase 2	Novo Nordisk A/S	12 mi
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes	Phase 2	Eli Lilly and Company	12 mi
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events	N/A	Cleerly, Inc.	46 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.